Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06898957 · ClinicalTrials.gov registry record · Phase 1
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
A Phase 1 study of Small-cell Lung Cancer, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT06898957: Recruiting Phase 1 study of Small-cell Lung Cancer, sponsored by Amgen.
NCT06898957 is a Phase 1 study of Small-cell Lung Cancer that is actively recruiting participants, run by Amgen. The registered enrollment target is 200 participants, below the 230-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (13% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06898957, a Phase 1 study of Small-cell Lung Cancer, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of tarlatamab in combination with YL201 with or without anti-PD-L1.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG Durvalumab
- DRUG Tarlatamab
- DRUG YL201
Study Locations (20)
Other
- Fujian Cancer Hospital - Fuzhou
- Institut Bergonie - Bordeaux
- Centre Leon Berard - Lyon
- Institut Universitaire du Cancer Toulouse Oncopole - Toulouse
- Gustave Roussy - Villejuif
- Universitaetsklinikum Essen - Essen
Washington
- Swedish Medical Center - Seattle
- Fred Hutchinson Cancer Center - Seattle
California
- City of Hope Orange County Lennar Foundation Cancer Center - Irvine
Connecticut
- Yale New Haven Hospital - New Haven
Florida
- Moffitt Cancer Center - Tampa
Massachusetts
- Dana Farber Cancer Institute - Boston
Missouri
- Siteman Cancer Center - St Louis
North Dakota
- Sanford Roger Maris Cancer Center - Fargo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-05-16 |
| Est. Completion | 2031-04-23 |
| Phase | Phase 1 |
What NCT06898957 shows while recruiting
NCT06898957 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 230-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (13% lower).
The record links to 1 condition, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Atezolizumab is the first listed.
NCT06898957 names 20 study sites across 14 states, led by Other, Washington, California.
Frequently Asked Questions
What is clinical trial NCT06898957 about?
NCT06898957 is a clinical study titled "Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)". The primary objective of this study is to evaluate the safety and tolerability of tarlatamab in combination with YL201 with or without anti-PD-L1.
What is the current status of trial NCT06898957?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2025-05-16. Estimated completion is 2031-04-23.
What conditions does trial NCT06898957 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer.
What interventions are being tested in trial NCT06898957?
The interventions under investigation include: Atezolizumab (DRUG), Durvalumab (DRUG), Tarlatamab (DRUG), YL201 (DRUG).
Who is sponsoring clinical trial NCT06898957?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06898957 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06898957's enrollment target sits among peer trials
200 27th of 79 higher than 53 of 79 other Small-cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Small-cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
RECRUITING · Phase 1
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI